Aduro BioTech, Inc., a clinical-stage biotechnology company, develops immunotherapy solutions for the treatment of cancer. The company develops a pipeline of new immunotherapies and immunotherapy combinations, including CRS-207, a solution based on Listeria platform to express the tumor-associated antigen mesothelin in patients with metastatic pancreatic cancer; and ADU-623, a clinical bivalent Listeria-based immunotherapy for patients with glioblastoma. It also develops ADU-214, a bivalent Listeria-based immunotherapy that targets mesothelin and EGFR mutations; ADU-741, a solution based on live-attenuated double-deleted immunotherapy platform for the treatment of prostate cancer; cyclic din...
626 Bancroft Way
Berkeley, CA 94710-2224
Founded in 2000
Aduro BioTech, Inc. Presents at BIO International Convention, Jun-25-2014 02:30 PM
Jun 17 14
Aduro BioTech, Inc. Presents at BIO International Convention, Jun-25-2014 02:30 PM. Venue: San Diego Convention Center, San Diego, California, United States.
Aduro BioTech, Inc. Announces ASCO Presentation of Promising Results from Phase 1b Clinical Trial of its Novel Immunotherapy for the Treatment of Mesothelioma
Jun 2 14
Aduro BioTech, Inc. announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). Of the 16 evaluable patients, 69% (11/16) had confirmed durable partial responses (PR) with 25% (4/16) experiencing stable disease (SD) after CRS-207 and chemotherapy. The results were presented by Raffit Hassan, M.D., co-chief of the Thoracic and GI Oncology Branch at the National Cancer Institute, in a poster presentation at the 2014 American Society of Clinical Oncology Meeting (ASCO) held in Chicago. CRS-207, based on Aduro's live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform, has been engineered to induce a potent innate immune response as well as an adaptive immune response targeting mesothelin, an antigen over-expressed in MPM tumors. The multi-center Phase 1b study enrolled 16 patients who were chemotherapy-naïve, had unresectable MPM, good performance status (ECOG 0 or 1) and adequate organ function. Under the trial design, eligible patients received two prime vaccinations with CRS-207 two weeks apart, followed by up to six cycles of standard of care pemetrexed and cisplatin chemotherapy three weeks apart and two CRS-207 boost vaccinations three weeks apart. Clinically stable patients are eligible to receive CRS-207 maintenance vaccinations every eight weeks. Subjects are followed every eight weeks until disease progression. Objectives of the study are safety, immunogenicity, objective tumor responses and tumor marker kinetics. As of March 31, the median time on study was 198 days (range: 88-402 days). No treatment-related serious adverse events or unexpected toxicities were observed. Treatment, follow-up and immune response evaluations are ongoing. Aduro also announced that Dung Le, M.D. provided an overview of the company's Phase 2b ECLIPSE clinical trial of CRS-207 as a monotherapy and in combination with GVAX Pancreas in patients with metastatic pancreatic cancer in a poster session at ASCO. The ECLIPSE trial (Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting) will involve over 20 clinical trial sites in the U.S. and Canada. The trial, which is randomized and controlled with three treatment arms, will evaluate the safety, immune response and efficacy of the combination immunotherapy of GVAX Pancreas (with low-dose cyclophosphamide (CY)) and CRS-207 compared to chemotherapy or to CRS-207 alone. The primary endpoint of the trial is overall survival. The ECLIPSE trial follows the completed, randomized, controlled, multicenter Phase 2 trial in 93 patients in the same population, in which a statistically significant survival benefit was demonstrated in patients receiving the combination of CY/GVAX Pancreas and CRS-207 immunotherapies (Arm A) compared to patients receiving CY/GVAX Pancreas immunotherapy alone (Arm B). The median overall survival for patients receiving the combination was 6.1 months compared to 3.9 months for those receiving GVAX monotherapy (HR=0.59, one-sided p=0.0172). Moreover, the immunotherapies were well-tolerated, with no treatment-related serious adverse events or unexpected toxicities observed. Mesothelioma and pancreatic cancer are among a number of potential applications for Aduro's LADD immunotherapy platform. Through a deal facilitated by the Johnson & Johnson Innovation center in California, Aduro announced last week that it has granted Janssen Biotech, Inc. an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform in a deal valued at up to $365 million. CRS-207 is one of a family of product candidates based on Aduro's live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform that induce a potent innate and T cell-mediated immune response. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers.
Janssen Biotech Inc Snags Cancer-Fighting Drug in Deal with Aduro
May 29 14
Aduro BioTech Inc. will receive an undisclosed upfront license fee as well as development, regulatory and commercialization milestone payments and royalties for granting J&J's Janssen Biotech Inc. an exclusive, worldwide license to the cancer immunotherapy treatment, known as ADU-741. Janssen will handle all research, development, manufacturing, regulatory and commercial work. ADU-741 rides shotgun with strains of the Listeria bacteria that are genetically modified so they can't be recombined in the body. Two genes are taken out of the bacteria and disease-specific antigens - foreign or toxic substances that trigger production of an antibody by the immune system - are added. Aduro's use of its live-attenuated double-deleted, or LADD, technology does more than rev up the body's innate immune response, which provides a short-term defense. It also alerts tumor-specific T cells that store away knowledge of the invader - so-called immunological memory - that protects against challenges from that pathogen over the long term. Aduro is continuing work with its LADD technology in pancreatic cancer, mesothelioma, non-small cell lung cancer and the brain cancer glioblastoma. In a separate deal, Janssen grabbed exclusive rights to Aduro's GVAX technology for prostate cancer. That cancer vaccine technology out of Cell Genesys Inc. of South San Francisco failed a Phase III clinical trial in prostate cancer but was ultimately snatched up by Aduro, which has combined it with Aduro's vaccine in pancreatic cancer studies.